Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Error message

    • Deprecated function: Return type of DatabaseStatementBase::execute($args = [], $options = []) should either be compatible with PDOStatement::execute(?array $params = null): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2246 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::current() should either be compatible with Iterator::current(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::next() should either be compatible with Iterator::next(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::key() should either be compatible with Iterator::key(): mixed, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::valid() should either be compatible with Iterator::valid(): bool, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).
    • Deprecated function: Return type of DatabaseStatementEmpty::rewind() should either be compatible with Iterator::rewind(): void, or the #[\ReturnTypeWillChange] attribute should be used to temporarily suppress the notice in require_once() (line 2348 of /var/www/webmd/apps/mdedge/htdocs/includes/database/database.inc).

    Sara Freeman

    News

    RA risk raised by work-related inhaled agents

    Author:
    Sara Freeman
    Publish date: December 15, 2022

    Exposure to detergents, dusts, and other chemicals in the workplace could be putting genetically susceptible people at risk of rheumatoid...

    • Read More

    News

    Gestational hypertension-diabetes combo signals CVD risk

    Author:
    Sara Freeman
    Publish date: December 2, 2022

    Having both hypertensive disorders and diabetes while pregnant ups later cardiovascular risk, suggesting greater care is needed when these...

    • Read More

    News

    Rituximab raises remission rate in granulomatosis with polyangiitis

    Author:
    Sara Freeman
    Publish date: November 30, 2022

    Remission at 6 months was recorded in 73.1% of rituximab-treated patients and 40.1% of cyclophosphamide-treated patients in a multicenter target...

    • Read More

    News

    52-week data show lebrikizumab atopic dermatitis effects maintained

    Author:
    Sara Freeman
    Publish date: October 5, 2022

    ADvocate1 and ADvocate2 are two of several phase 3 trials evaluating the efficacy and safety of lebrikizumab for the treatment of atopic...

    • Read More

    News

    Ruxolitinib repigments many vitiligo-affected body areas

    Author:
    Sara Freeman
    Publish date: October 5, 2022

    Ruxolitinib is a Janus kinase 1/2 inhibitor that has been available for the treatment for atopic dermatitis for more than a year.

    • Read More

    News

    BREEZE-AD-PEDS: First data for baricitinib in childhood eczema reported

    Author:
    Sara Freeman
    Publish date: October 4, 2022

    Treatment with the oral JAK inhibitor was significantly more effective than placebo only with the highest dose evaluated.

    • Read More

    News

    Alopecia areata: Positive results reported for two investigational JAK inhibitors

    Author:
    Sara Freeman
    Publish date: September 30, 2022

    “This is truly transformative therapy,” one of the investigators, Brett King, MD, PhD, said.

    • Read More

    News

    Study identifies skin biomarkers that predict newborn eczema risk

    Author:
    Sara Freeman
    Publish date: September 30, 2022

    "We are able to identify predictive immune biomarkers of atopic dermatitis using a noninvasive method," the investigator said.

    • Read More

    News

    Ezetimibe-statin combo lowers liver fat in open-label trial

    Author:
    Sara Freeman
    Publish date: September 30, 2022

    A significant 5.8% decrease in hepatic steatosis was seen after 24 weeks’ treatment with ezetimibe and rosuvastatin comparing baseline with end of...

    • Read More

    News

    Early age at hysterectomy ups type 2 diabetes risk

    Author:
    Sara Freeman
    Publish date: September 23, 2022

    Having a hysterectomy appears to increase the risk of incident type 2 diabetes, particularly in younger women, and if the ovaries are removed at...

    • Read More

    News

    Mothers’ diabetes linked to ADHD in their children

    Author:
    Sara Freeman
    Publish date: September 22, 2022

    A small increased risk of ADHD in children born to mothers with diabetes, including pregestational diabetes and gestational diabetes, has been...

    • Read More

    News

    Apremilast alleviates severe psoriasis in some children, data show

    Author:
    Sara Freeman
    Publish date: September 20, 2022

    “In this randomized, placebo-controlled trial, oral apremilast demonstrated effectiveness and was well tolerated.”

    • Read More

    News

    Hope shines bright for hidradenitis suppurativa treatments

    Author:
    Sara Freeman
    Publish date: September 19, 2022

    Research into HS is "an incredibly active field at this moment," said Alexa B. Kimball, MD, MPH.

    • Read More

    News

    Experts express caution over
    type 2 diabetes/tea-drinking claim

    Author:
    Sara Freeman
    Publish date: September 17, 2022

    Drinking four cups of tea a day was linked to a 17% lower risk for developing type 2 diabetes in a study, but experts warn these data are...

    • Read More

    News

    Roflumilast foam effectively eases seborrheic dermatitis

    Author:
    Sara Freeman
    Publish date: September 13, 2022

    The study evaluated a foam formulation of roflumilast, a PDE4 inhibitor that is available for topical use in a cream formulation that was recently...

    • Read More

    Pages

    • « first
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2023 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery